26.05.2010 • News

FDA: J&J Unit Needs More Inspection After Lapses

The U.S. Food and Drug Administration (FDA) is calling for further inspection and an outside audit of a Johnson & Johnson unit following manufacturing lapses.

The FDA, in a warning letter made public on Tuesday, cited multiple problems at Advanced Sterilization Products, a division of J&J's Ethicon, including failures to verify design changes needed to make sure devices work properly. The division also did not ensure that finished devices met necessary requirements, among other violations, the FDA wrote March 12.

The Irvine, Calif.-based division makes various sterilizers and cleaning devices, including Sterrad, Evotech and Cidex products, according to the agency. The company's responses to the FDA so far have been inadequate, the agency said.

In a statement, J&J told Reuters that Advanced Sterilization Products "has aggressively implemented a number of specific corrective actions to address deficiencies in some of our internal processes" and would continue to work with the FDA. It also noted that the letter did not prohibit the company from selling its products, which it said were safe and effective when used as directed.

The FDA said a follow-up agency inspection of the Johnson & Johnson unit will be required. It also requested an audit and certification by an outside expert consultant. FDA's letter was posted on the agency website.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.